Serum-to-urinary prostate-specific antigen ratio: A potential means of distinguishing benign prostatic hyperplasia from prostate cancer

被引:0
|
作者
Irani, J
Millet, C
Levillain, P
Dore, B
Begon, F
Aubert, J
机构
[1] CHU LA MILETRIE,DEPT NUCL MED,F-86000 POITIERS,FRANCE
[2] CHU LA MILETRIE,DEPT PATHOL,F-86000 POITIERS,FRANCE
关键词
prostatic neoplasms; prostate-specific antigen; prostatic hypertrophy; prostatitis;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: High concentrations of serum prostate-specific antigen (PSA) may be associated with the presence of benign prostatic hyperplasia or prostatitis. We investigated the serum-to-urinary PSA ratio in patients with or without prostate cancer to assess its efficacy in enhancing serum PSA specificity. Methods: Patients presenting abnormal findings in digital rectal examination or documented prostate carcinoma were prospectively included in the study. A control group, with no evidence of prostate disease, hospitalized in the same time interval was included. Serum and urine PSA levels were measured in our laboratory with the Tandem R assay (Hybritech). Samples were drawn twice at 2-month intervals (M1 and M3). Results: Sixty-eight patients were included in the study divided into 27 cases of benign prostatic hyperplasia, 20 of prostate carcinoma, 10 of prostatitis and 11 patients in the control group. Serum and urine PSA levels were not correlated (r less than or equal to \0.1\). There was no significant difference in any group from M1 to M3 as regards urinary PSA (p greater than or equal to 0.15). Intergroup comparison showed significantly (p less than or equal to 0.004) high urinary PSA (mean level +/- SEM 28.3 +/- 3.4 mu g/mmol creatinine) only in the benign prostatic hyperplasia group, mean levels in the prostate carcinoma, prostatitis and control groups being 3.7 +/- 1.1, 11 +/- 2.9 and 5.2 +/- 0.9 mu g/mmol creatinine, respectively. Differences in urinary PSA levels between the confined prostate carcinoma and benign prostatic hyperplasia groups (p = 0.0008) were further increased when considering the serum-to-urinary PSA ratio (p = 0.0003). Conclusion: Our results suggest that the serum-to-urinary PSA ratio may be useful in distinguishing benign prostatic hyperplasia from prostate cancer.
引用
收藏
页码:407 / 412
页数:6
相关论文
共 50 条
  • [1] Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer
    Hillenbrand, M
    Bastian, M
    Steiner, M
    Zingler, C
    Müller, M
    Wolff, JM
    Seiter, H
    Schuff-Werner, P
    [J]. ANTICANCER RESEARCH, 2000, 20 (6D) : 4995 - 4996
  • [2] MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN AND GAMMA-SEMINOPROTEIN RATIO - A NEW MEANS OF DISTINGUISHING BENIGN PROSTATIC HYPERPLASIA AND PROSTATE-CANCER
    DEMURA, T
    WATARAI, Y
    TOGASHI, M
    HIRANO, T
    OHASHI, N
    KOYANAGI, T
    [J]. JOURNAL OF UROLOGY, 1993, 150 (05): : 1740 - 1745
  • [3] Benign prostatic hyperplasia and prostate-specific antigen
    Pejcic, Tomislav
    Acimovic, Miodrag
    Dzamic, Zoran
    Radovanovic, Milan
    Hadzi-Djokic, Jovan
    [J]. VOJNOSANITETSKI PREGLED, 2015, 72 (05) : 447 - 453
  • [4] Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?
    Pejcic, Tomislav P.
    Tulic, Cane Dz
    Lalic, Natasa V.
    Glisic, Biljana D.
    Ignjatovic, Svetlana D.
    Markovic, Biljana B.
    Hadzi-Djokic, Jovan B.
    [J]. CANADIAN JOURNAL OF UROLOGY, 2013, 20 (02) : 6707 - 6713
  • [5] Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia
    Roehrborn, CG
    Boyle, P
    Gould, AL
    Waldstreicher, J
    [J]. UROLOGY, 1999, 53 (03) : 581 - 589
  • [6] Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression
    Levitt J.M.
    Slawin K.M.
    [J]. Current Urology Reports, 2007, 8 (4) : 269 - 274
  • [7] Free-to-total prostate-specific antigen serum concentrations in patients with prostate cancer and benign prostatic hyperplasia
    Wolff, JM
    Borchers, H
    Effert, PJ
    Habib, FK
    Jakse, G
    [J]. BRITISH JOURNAL OF UROLOGY, 1996, 78 (03): : 409 - 413
  • [8] Serum-to-urinary prostate specific antigen ratio: Its impact in distinguishing prostate cancer when serum prostate specific antigen level is 4 to 10 NG/ML.
    Irani, J
    Millet, C
    Levillain, P
    Dore, B
    Begon, F
    Aubert, J
    [J]. JOURNAL OF UROLOGY, 1997, 157 (01): : 185 - 188
  • [9] Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia
    Hsiao, Chun-Jen
    Tzai, Tzong-Shin
    Chen, Chein-Hung
    Yang, Wen-Horng
    Chen, Chung-Hsuan
    [J]. DISEASE MARKERS, 2016, 2016
  • [10] Urinary/serum prostate-specific antigen ratio:: Comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection
    Irani, J
    Salomon, L
    Soulié, M
    Zlotta, A
    de la Taille, A
    Doré, B
    Millet, C
    [J]. UROLOGY, 2005, 65 (03) : 533 - 537